NEW YORK (GenomeWeb) – Cepheid announced today that it has received clearance from the US Food and Drug Administration for its Xpert MRSA NxG, a test for methicillin-resistant Staphylococcus aureus (MRSA) infection.

The test runs on the GeneXpert molecular diagnostic system and delivers results in around an hour, the company noted. To develop the test, Cepheid used an extensive library of MRSA strains collected around the world, and it included updated PCR primers and probes that detect both mecA and mecC strains, which reduces the frequency of false-positive results.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.